Sign In
Buy FULC
$3.58
-0.140 (-3.76%)
At Close: Jul 31, 2026
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 19'th Jan 2021
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer
04:00pm, Tuesday, 19'th Jan 2021
Owen Wallace to Transition to Scientific Advisory Board Owen Wallace to Transition to Scientific Advisory Board
Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
07:00am, Wednesday, 09'th Dec 2020
Event will review the company's novel approach to inducing fetal hemoglobin
CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
07:30am, Friday, 13'th Nov 2020
CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q3 2020 Results - Earnings Call Transcript
12:45pm, Tuesday, 10'th Nov 2020
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q3 2020 Results - Earnings Call Transcript
Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
04:01pm, Wednesday, 04'th Nov 2020
Screening of healthy volunteers initiated in Phase 1 clinical trial of FTX-6058 Screening of healthy volunteers initiated in Phase 1 clinical trial of FTX-6058
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Point72 Asset Management established new holdings in Fulcrum Therapeutics, Inc.
12:00am, Friday, 02'nd Oct 2020
Point72 Asset Management established new holdings in Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics'(NASDAQ:FULC) Share Price Is Down 33% Over The Past Year.
06:49pm, Tuesday, 18'th Aug 2020
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...
Fulcrum Therapeutics, Inc. 2020 Q2 - Results - Earnings Call Presentation
05:14pm, Thursday, 13'th Aug 2020
The following slide deck was published by Fulcrum Therapeutics, Inc. in conjunction with their 2020 Q2 earnings call..
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
11:01am, Tuesday, 11'th Aug 2020
– Conference call scheduled for 8:00 a.m. ET today – CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focu
Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
11:00am, Tuesday, 11'th Aug 2020
Reduction in DUX4-driven gene expression observed in biopsies with highest baseline levels of DUX4-driven gene expressionTopline data on-track for Q1 2021 with full data in Q2 2021 Company to review c
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.38%
12:00am, Tuesday, 11'th Aug 2020
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.38%
Why Earnings Season Could Be Great for Fulcrum Therapeutics (FULC)
01:43pm, Monday, 10'th Aug 2020
Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
